151 related articles for article (PubMed ID: 25788219)
21. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
22. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
[TBL] [Abstract][Full Text] [Related]
23. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study.
Luo Y; Zhang Y; Wang D; Shen D; Che YQ
Cancer Manag Res; 2020; 12():5323-5330. PubMed ID: 32753950
[TBL] [Abstract][Full Text] [Related]
24. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma.
Wahb AMSE; El Kassas M; Khamis AK; Elhelbawy M; Elhelbawy N; Habieb MSE
World J Hepatol; 2021 Nov; 13(11):1753-1765. PubMed ID: 34904043
[TBL] [Abstract][Full Text] [Related]
25. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma.
Merchante N; Merino E; Rodríguez-Arrondo F; Tural C; Muñoz J; Delgado-Fernández M; Jover F; Galindo MJ; Rivero A; López-Aldeguer J; Aguirrebengoa K; Romero-Palacios A; Martínez E; Pineda JA
AIDS; 2014 Jan; 28(1):41-7. PubMed ID: 24056067
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR.
Yeh ML; Liang PC; Tsai PC; Wang SC; Leong J; Ogawa E; Jun DW; Tseng CH; Landis C; Tanaka Y; Huang CF; Hayashi J; Hsu YC; Huang JF; Dai CY; Chuang WL; Nguyen MH; Yu ML
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298669
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients.
Merchante N; Rodríguez-Arrondo F; Revollo B; Merino E; Ibarra S; Galindo MJ; Montero M; García-Deltoro M; Rivero-Juárez A; Téllez F; Delgado-Fernández M; Ríos-Villegas MJ; García MA; Vera-Méndez FJ; Ojeda-Burgos G; López-Ruz MA; Metola L; Omar M; Alemán-Valls MR; Aguirrebengoa K; Portu J; Raffo M; Macías J; Pineda JA;
AIDS; 2018 Jul; 32(11):1423-1430. PubMed ID: 29596108
[TBL] [Abstract][Full Text] [Related]
28. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
29. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
[TBL] [Abstract][Full Text] [Related]
30. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
31. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
32. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.
Toyoda H; Tada T; Tsuji K; Hiraoka A; Tachi Y; Itobayashi E; Takaguchi K; Senoh T; Takizawa D; Ishikawa T; Kumada T
Hepatol Res; 2016 Jul; 46(8):734-42. PubMed ID: 26508201
[TBL] [Abstract][Full Text] [Related]
34. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.
Tanaka A; Uegaki S; Kurihara H; Aida K; Mikami M; Nagashima I; Shiga J; Takikawa H
World J Gastroenterol; 2007 Oct; 13(39):5180-7. PubMed ID: 17876888
[TBL] [Abstract][Full Text] [Related]
35. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
[TBL] [Abstract][Full Text] [Related]
36. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
37. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
[TBL] [Abstract][Full Text] [Related]
39. Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection.
Miquelestorena-Standley E; Tallet A; Collin C; Piver E; De Muret A; Salamé E; Bourlier P; Kervarrec T; Guyétant S; Pagès JC
Hepatol Res; 2018 Jun; 48(7):566-573. PubMed ID: 28512857
[TBL] [Abstract][Full Text] [Related]
40. Circulating miRNA-122, miRNA-199a, and miRNA-16 as Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.
El-Abd NE; Fawzy NA; El-Sheikh SM; Soliman ME
Mol Diagn Ther; 2015 Aug; 19(4):213-20. PubMed ID: 26133725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
